Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1. ...

In its upcoming report, Steris (STE) is predicted by Wall Street analysts to post quarterly earnings of $2.03 per share, reflecting an increase of 1.5% compared to the same period last year. Revenues are forecasted to be $1.26 billion, representing a year-over-year decrease of 1.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Ahead of a c ...

DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024. Additional information about the U.S. tax treatment of dividends, including require ...

DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024. Additional information about the U.S. tax treatment of dividends, including require ...

A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, the ...

About STERIS Company Contact: Julie_Winter@steris.com CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION adversely impact STERIS's provision for income taxes and effective tax rate and subject STERIS to additional income tax in jurisdictions who adopt Pillar Two Model Rules, (g) STERIS's ability to continue to qualify for benefits under certain income tax treaties in light of ratification of more strict income tax treaty rules (through the MLI) in many jurisdictions where STERIS has operations, (h) ...

Earnings Surprise History STERIS plc (STE) is expected to release first-quarter fiscal 2025 results on Aug 6. Healthcare We assume the Healthcare backlog to have finally normalized during the fiscal first quarter, as the company might have been able to ship at a faster pace than the new orders. STERIS' focus on getting back to normal lead times must have helped it in meeting customer demand. Our model projects the segment's revenues to improve 7.1% from the year-ago reported figure. Within the segment, the ...

STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain these equipments, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. Over the past few quarters, the segment's organic growth has been driven by the continuous procedure volume growth in the United States and favorable pricing and market share gains ...

Meanwhile, the impacts of macroeconomic challenges and increasing consolidation in the industry pose a worry for the stock. The renowned provider of infection prevention and other procedural products and services has a market capitalization of $21.75 billion. The company has an earnings yield of 4.20% compared to the industry's -5.82%. In the trailing four quarters, STE delivered an average earnings surprise of 2.21%. Factors at Play Optimistic Forecast for the AST Segment: The business offers a wide range ...

STERIS' (STE) strong rebound of procedure volumes in the United States is leading to solid growth in the Healthcare business. Yet, a fiercely competitive market offsets the positive. The stock carries a Zacks Rank #3 (Hold) at present. STERIS' Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource i ...